Compare Futu Holdings Ltd (FUTU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Merck & Co., Inc. — how do they compare? Futu Holdings Ltd trades at $98.3 (market cap $13.94B), while Merck & Co., Inc. trades at $127.81 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 21.9× Futu Holdings Ltd's market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| FUTU | MRK | |
|---|---|---|
Market Cap | $13.94B | $305.29B |
Sector | Financials | Health |
52-Week High | $199.04 | $129.52 |
52-Week Low | $89.76 | $77.60 |
Enterprise Value | $13.79B | $348.71B |
Dividend Yield | 2.62% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUTU trades at $98.2, up 0.07% on the day, with a bullish technical signal but mixed earnings history including a Q1 2026 miss. The company shows strong fundamentals with 2025 revenue of $22.85B, net income margin of 49.62%, and robust cash flow. However, multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The outlook is clouded by legal risks despite solid profitability and analyst support (58% buy ratings). Investment opportunity hinges on resolution of regulatory allegations, while key risks include potential financial penalties and reputational damage from ongoing litigation.
Merck (MRK) trades at $128.00, up 5.96% on the day. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal robust profitability with a 73.91% gross margin and consistent earnings beats in recent quarters. The company is actively expanding its oncology pipeline through acquisitions, most notably the $6.7 billion tender offer for Terns Pharmaceuticals announced in April 2026.
The outlook is positive, supported by strong analyst consensus (67.57% Buy rating) and a price target implying ~7% upside. Key opportunities include pipeline expansion via M&A and solid cash flow generation. Primary risks involve integration of large acquisitions, patent cliffs for key drugs, and intense competition in the oncology space, which could pressure future growth margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
